Literature DB >> 20538017

Application of an inducible system to engineer unmarked conditional mutants of essential genes of Pseudomonas aeruginosa.

Yuji Morita1, Shin-ichiro Narita, Junko Tomida, Hajime Tokuda, Yoshiaki Kawamura.   

Abstract

The Phi CTX-based integration vector pYM101 harboring a tightly controlled modified phage T7 early gene promoter/LacI(q) repressor (T7/LacI) system was constructed for the generation of unmarked conditional mutants in Pseudomonas aeruginosa. Promoter activity of the T7/LacI system was demonstrated to be dependent on the presence of the inducer isopropyl -beta-D-1-thiogalactopyranoside (IPTG), as evaluated by measuring beta-galactosidase activity. In the absence of the inducer, the promoter was silent as its activity was lower than those of a promoter-less lacZ control. Unmarked conditional mutants of four predicted essential genes (lolCDE (PA2988-86), lpxC (PA4406), rho (PA5239), and def (PA0019)) were successfully constructed using this recombination system. In the absence of IPTG, the growth of all mutants was repressed; however, the addition of either 0.1 or 1mM IPTG restored growth rates to levels nearly identical to wild-type cells. It was therefore demonstrated that the inducible integration vector pYM101 is suitable for the creation of unmarked conditional mutants of P. aeruginosa, and is particularly useful for examining the function of essential genes. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538017     DOI: 10.1016/j.mimet.2010.06.001

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  9 in total

1.  A new family of bacterial condensins.

Authors:  Zoya M Petrushenko; Weifeng She; Valentin V Rybenkov
Journal:  Mol Microbiol       Date:  2011-07-18       Impact factor: 3.501

2.  SraL sRNA interaction regulates the terminator by preventing premature transcription termination of rho mRNA.

Authors:  Inês Jesus Silva; Susana Barahona; Alex Eyraud; David Lalaouna; Nara Figueroa-Bossi; Eric Massé; Cecília Maria Arraiano
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

3.  Identification of novel genes responsible for overexpression of ampC in Pseudomonas aeruginosa PAO1.

Authors:  Yuko Tsutsumi; Haruyoshi Tomita; Koichi Tanimoto
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

4.  Pseudomonas aeruginosa Condensins Support Opposite Differentiation States.

Authors:  Hang Zhao; April L Clevenger; Jerry W Ritchey; Helen I Zgurskaya; Valentin V Rybenkov
Journal:  J Bacteriol       Date:  2016-10-07       Impact factor: 3.490

5.  MexXY multidrug efflux system of Pseudomonas aeruginosa.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2012-11-28       Impact factor: 5.640

6.  A truncated AdeS kinase protein generated by ISAba1 insertion correlates with tigecycline resistance in Acinetobacter baumannii.

Authors:  Jun-Ren Sun; Cherng-Lih Perng; Ming-Chin Chan; Yuji Morita; Jung-Chung Lin; Chih-Mao Su; Wei-Yao Wang; Tein-Yao Chang; Tzong-Shi Chiueh
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

Review 7.  Responses of Pseudomonas aeruginosa to antimicrobials.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2014-01-08       Impact factor: 5.640

8.  Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2015-01-21       Impact factor: 5.640

9.  Berberine Is a Novel Type Efflux Inhibitor Which Attenuates the MexXY-Mediated Aminoglycoside Resistance in Pseudomonas aeruginosa.

Authors:  Yuji Morita; Ken-Ichi Nakashima; Kunihiko Nishino; Kenta Kotani; Junko Tomida; Makoto Inoue; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2016-08-05       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.